EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY-NC 4.0

Efficacy and safety of oral semaglutide in Chinese participants with type 2 diabetes: Subgroup analyses by baseline characteristics in the PIONEER 11 and 12 randomised controlled trials

Linong Ji iD, Guoyue Yuan iD, Jun Liu, Bingjie Zhang, Wenyan Liu, Zewei Shen

Diabetes, Obesity and Metabolism · 2025

DOI: 10.1111/dom.70031 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Diabetes, Obesity and Metabolism, 2025. Verfasst von Linong Ji und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology and Metabolism, Peking University People's Hospital, Beijing, China. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Hypoglycemic Agents, Sitagliptin Phosphate, East Asian People. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Novo Nordisk Shanghai (Ltd).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

This post hoc analysis investigates the impact of baseline characteristics on the efficacy and safety of oral semaglutide in a Chinese population with type 2 diabetes. Materials and Methods Chinese participants from the PIONEER 11 and 12 trials with type 2 diabetes aged ≥18 years were randomised to once‐daily oral semaglutide 3, 7, or 14 mg, or placebo (PIONEER 11) or sitagliptin 100 mg (PIONEER 12). Changes from baseline in HbA 1c and body weight at week 26 were analysed in subgroups according to the following baseline characteristics: age, HbA 1c , body mass index, duration of diabetes, and presence of gastrointestinal disease. Adverse events (AEs) by baseline subgroups were also assessed.

Results

In total, 390 (PIONEER 11) and 1084 (PIONEER 12) Chinese participants with type 2 diabetes were evaluated. Most baseline characteristics were similar across the two trials in the different subgroups. Overall, greater reductions in HbA 1c and body weight were observed with oral semaglutide versus comparators across the subgroups. A significant difference was observed for change in HbA 1c by baseline HbA 1c subgroups ( p int

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Hypoglycemic AgentsSitagliptin PhosphateEast Asian PeopleGlucagon-Like Peptide 1AdultAgedFemaleHumansMaleMiddle AgedAdministration, OralBlood GlucoseBody WeightChinaDouble-Blind MethodGlycated HemoglobinTreatment OutcomeSemaglutide

Stichwörter der Autor:innen

GLP‐1RAHbA1cbody weightoral semaglutidesafetytype 2 diabetes

Substanzen

Blood GlucoseGlycated HemoglobinHypoglycemic AgentsSitagliptin PhosphateGlucagon-Like Peptide 1Semaglutidehemoglobin A1c protein, human

Autor:innen und Institutionen

  • Department of Endocrinology and Metabolism, Peking University People's Hospital, Beijing, China.
  • Department of Endocrinology, The Affiliated Hospital of Jiangsu University, Zhenjiang, China.
  • Department of Endocrinology, Shanghai Fifth People's Hospital, Fudan University, Shanghai, China.
  • Novo Nordisk (Shanghai) Pharma Trading Co., Ltd, Beijing, China.

ORCID-Profile: Linong Ji, Guoyue Yuan

Förderung

  • Novo Nordisk Shanghai (Ltd)

Zitieren

APA

Ji, L., Yuan, G., Liu, J., Zhang, B., Liu, W., & Shen, Z. (2025). Efficacy and safety of oral semaglutide in Chinese participants with type 2 diabetes: Subgroup analyses by baseline characteristics in the PIONEER 11 and 12 randomised controlled trials. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.70031

Vancouver

Ji L, Yuan G, Liu J, Zhang B, Liu W, Shen Z. Efficacy and safety of oral semaglutide in Chinese participants with type 2 diabetes: Subgroup analyses by baseline characteristics in the PIONEER 11 and 12 randomised controlled trials. Diabetes, Obesity and Metabolism. 2025. doi:10.1111/dom.70031

BibTeX
@article{Ji2025,
  author = {Ji, Linong and Yuan, Guoyue and Liu, Jun and Zhang, Bingjie and Liu, Wenyan and Shen, Zewei},
  title = {Efficacy and safety of oral semaglutide in Chinese participants with type 2 diabetes: Subgroup analyses by baseline characteristics in the PIONEER 11 and 12 randomised controlled trials},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2025},
  doi = {10.1111/dom.70031}
}
Kostenlos starten →